Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...